The early and precise treatment of high-risk non-disabling ischemic cerebrovascular event (HR-NICE) has directly influenced on prognosis, and it attracts more attention. Although intravenous thrombolysis is generally acknowledged as the most effective therapy for ischemic stroke, but it is still in dispute for HR-NICE. This article reviews the domestic and abroad progress in HR-NICE in recent years.